Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Remergent HQ
- Development stage
- Unknown
- Lead developer
- Applied Genetics Inc. Dermatics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Remergent HQ is a topical skin-lightening product formulated as a cream containing 4% hydroquinone. It is indicated for the treatment of hyperpigmentation conditions such as melasma, chloasma, freckles, senile lentigines, and post-inflammatory hyperpigmentation. The mechanism of action involves the inhibition of the enzyme tyrosinase, which is essential for the conversion of tyrosine to melanin within melanocytes. By blocking this pathway, Remergent HQ reduces the production of melanin pigment and promotes the depigmentation of darkened skin areas. It is typically applied twice daily to the affected regions.
- Brand names
- Remergent HQ
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on Remergent HQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Remergent HQ.